Engineered Migrasomes: A Robust, Thermally Stable Vaccination Platform

Dongju Wang,Haifang Wang,Wei Wan,Zihui Zhu,Takami Sho,Yi Zheng,Xing Zhang,Longyu Dou,Qiang Ding,Li Yu,Zhihua Liu

DOI: https://doi.org/10.1101/2024.03.13.584850

2024-03-14

Abstract:The burgeoning abilities of pathogens and tumor cells to evade immune responses underscore the urgent need for innovative vaccination platforms based on a variety of biological mechanisms. The current logistical challenges associated with cold-chain (i.e. low-temperature) transportation particularly impacts access to vaccines in the global south. We recently discovered organelles called migrasomes, and herein we investigate the potential of migrasomes as an alternative vaccination platform. Their inherent stability and their enrichment with immune-modulating molecules make migrasomes promising candidates, but their low yield presents a hurdle. We address this problem through our engineered migrasome-like vesicles (eMigrasomes), which emulate the biophysical attributes of natural migrasomes with substantially improved yield. We show that eMigrasomes loaded with a model antigen elicit potent antibody responses and maintain stability at room temperature. We demonstrate that eMigrasomes bearing the SARS-CoV-2 Spike protein induce robust humoral protection against the virus. Our study demonstrates the potential of eMigrasome-based vaccines as a unique, robust, and accessible alternative to traditional methods.

Cell Biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a new - type vaccine platform to overcome the limitations of existing vaccines in terms of transportation and storage requirements, especially the impact of cold - chain transportation on vaccine access in the global South. The paper introduces a vaccine platform based on engineered migrasome - like vesicles (eMigrasomes) derived from migrasomes.

**Specific problems include**:

1. **Improving vaccine stability**: Many existing vaccines need to be transported and stored under low - temperature conditions, which is a major challenge in resource - limited or remote areas. The research in the paper aims to develop a vaccine platform that can remain stable at room temperature to improve vaccine accessibility and ease of use.

2. **Enhancing the immune response**: By using eMigrasomes as carriers, the research team hopes to improve the immunogenicity of vaccines, that is, the ability of vaccines to induce the body to produce an immune response. The paper shows that eMigrasomes can effectively load antigens and induce a strong antibody response in a mouse model.

3. **Reducing vaccine production costs**: Traditional vaccine production methods are often costly and have limited yields. The paper mentions that by optimizing the method of generating eMigrasomes, its yield can be significantly increased, which may reduce the production cost of vaccines.

**Research background**:

- Pathogens and tumor cells are increasingly capable of evading immune responses, and there is an urgent need for innovative vaccine platforms based on different biological mechanisms.
- The great success of mRNA vaccines in the fight against the COVID - 19 pandemic further proves the importance of developing vaccine platforms based on different basic biological principles.
- However, the application of mRNA vaccines and other traditional vaccines is limited by complex low - temperature transportation requirements, especially in the global South, where this limitation is particularly evident.

**Solutions**:

- **Engineered migrasome - like vesicles (eMigrasomes)**: The research team has developed a new type of engineered migrasome - like vesicles by simulating the biophysical properties of natural migrasomes. These vesicles have high yield, high stability, and good immunogenicity.
- **Antigen loading**: eMigrasomes can effectively load model antigens (such as ovalbumin OVA) and the SARS - CoV - 2 spike protein (S protein) and induce a strong antibody response in a mouse model.
- **Room - temperature stability**: eMigrasomes exhibit extremely high stability at room temperature. Even after 14 days, there are little changes in their morphology and quantity, and their immunogenicity is not affected.

In conclusion, this research provides a new, eMigrasomes - based vaccine platform with the advantages of high stability, high efficiency, and ease of production, and is expected to become an important vaccine technology in the future.